Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Abstract Background This research aimed to assess the efficacy and safety of combining sintilimab with bevacizumab, oxaliplatin, and capecitabine as a primary therapy for patients with RAS-mutated, microsatellite stable (MSS), and metastatic colorectal cancer (mCRC). Methods In this prospective, ope...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-03-01
|
| Seri Bilgileri: | BMC Cancer |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12885-025-13794-w |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|